Pacific Edge Limited (ASX:PEB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0980
0.00 (0.00%)
Jul 18, 2025, 9:59 AM AEST

Pacific Edge Company Description

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients.

It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.

It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence.

In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma.

Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Pacific Edge Limited
CountryNew Zealand
Founded2001
IndustryDiagnostics & Research
SectorHealthcare
Employees114
CEOPeter Meintjes

Contact Details

Address:
Centre for Innovation
Dunedin, 9016
New Zealand
Phone64 3 577 6733
Websitepacificedgedx.com

Stock Details

Ticker SymbolPEB
ExchangeAustralian Securities Exchange
Fiscal YearApril - March
Reporting CurrencyNZD
ISIN NumberNZPEBE0002S1
SIC Code2835

Key Executives

NamePosition
Dr. Peter MeintjesChief Executive Officer
Grant GibsonChief Financial Officer
Darrell MorganChief Operating Officer
Dr. Justin HarveyChief Technology Officer
Prof. Parry Guilford Ph.D.Chief Scientific Officer and Member of Scientific Advisory Board
Zoe O'DonnellGlobal Head of People and Culture
Andrew McIntoshChief Digital Officer
Glen CostinPresident of Asia Pacific
Dr. Tamer AboushwarebChief Medical Officer
David LevisonExecutive Chairman and President of Pacific Edge Diagnostics USA